FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to the bioproduction of hyaluronic acid. Disclosed is a recombinant cell containing a plurality of modifications, as described in present text. Present invention additionally relates to methods providing bioproduction of hyaluronic acid, having controlled molecular weight, using genetically modified cells according to invention.
EFFECT: invention makes it possible to cost-effectively obtain large quantities of hyaluronic acid of a certain and controlled size that is safe for human use.
26 cl, 2 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| YEAST PRODUCING EKTOIN | 2018 |
|
RU2745157C1 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| NUCLEOTIDE SEQUENCE ENCODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN Dll4 AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2021 |
|
RU2787060C1 |
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| BISPECIFIC ANTIBODIES BINDING TO TFR | 2019 |
|
RU2810756C2 |
| NEW POLYPEPTIDE AND METHOD OF PRODUCING L-LEUCINE USING ITS | 2021 |
|
RU2811433C1 |
| RECOMBINANT PRODUCTION OF STEVIOL GLYCOSIDES | 2014 |
|
RU2741103C2 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
